Related Experiment Video
Updated: Apr 23, 2026

Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function
Published on: April 12, 2024
Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of
Eeva Piitulainen1, Laura Cano Montero, Meltem Nystedt-Düzakin
11Departments of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University , Malmö , Sweden.
Insights
Alpha-1-antitrypsin (AAT) deficiency in never-smokers shows no emphysema signs at age 35. However, AAT deficiency individuals who smoke show early emphysema indicators, highlighting smoking
Area of Science:
- Pulmonary Medicine
- Genetics
- Radiology
Background:
- Alpha-1-antitrypsin (AAT) deficiency is a known genetic risk factor for developing pulmonary emphysema.
- A nationwide screening of Swedish newborns in 1972-1974 identified individuals with AAT deficiency.
Purpose of the Study:
- To assess for early signs of emphysema in individuals with PiZZ and PiSZ AAT deficiency genotypes at 35 years of age.
- To investigate the role of smoking as a modifier in the development of emphysema in AAT-deficient individuals.
Main Methods:
- Pulmonary function tests (PFTs) and CT densitometry were performed on study participants.
- Key metrics analyzed included the fifteenth percentile density (PD15) and relative area below -910 HU (RA-910).
- Comparison was made between AAT-deficient genotypes (PiZZ, PiSZ) and PiMM control subjects, stratified by smoking status.
Main Results:
- Never-smoking AAT-deficient individuals (PiZZ, PiSZ) exhibited normal lung function compared to never-smoking controls (PiMM).
- PiZZ ever-smokers demonstrated significantly lower carbon monoxide transfer coefficient (KCO) compared to PiSZ and PiMM never-smokers.
- CT densitometry revealed significantly lower PD15 in PiZZ ever-smokers compared to ever-smoking controls, suggesting early emphysematous changes.
Conclusions:
- AAT deficiency alone does not appear to cause significant lung function impairment or emphysema in never-smokers by age 35.
- Smoking exacerbates the effects of AAT deficiency, with PiZZ ever-smokers showing potential early signs of emphysema.
- These findings underscore the critical role of smoking cessation in managing AAT deficiency to prevent or delay the onset of pulmonary emphysema.
Abstract:
Alpha-1-antitrypsin (AAT) deficiency is a genetic risk factor for pulmonary emphysema. In 1972-74 all 200,000 Swedish new-born infants were screened for AAT deficiency. The aim of the present study was to investigate whether the PiZZ and PiSZ individuals identified by this screening have signs of emphysema and the role of smoking in this, compared with a random sample of control subjects at 35 years of age. The study participants underwent complete pulmonary function tests (PFT) and CT densitometry. The fifteenth percentile density (PD15) and the relative area below -910 HU (RA-910) were analyzed. Fifty-four PiZZ, 21 PiSZ and 66 PiMM control subjects participated in the study. No significant differences were found in lung function between the never-smoking AAT-deficient and control subjects. The 16 PiZZ ever-smokers had significantly lower carbon monoxide transfer coefficient (KCO) than the 20 PiSZ never-smokers (p = 0.014) and the 44 PiMM never-smokers (p = 0.005). After correction for the CT derived lung volume, the PiZZ ever-smokers had significantly lower PD15 (p = 0.046) than the ever-smoking controls. We conclude that 35-year-old PiZZ and PiSZ never-smokers have normal lung function when compared with never-smoking control subjects. The differences in KCO and CT densitometric parameters between the PiZZ ever-smokers and the control subjects may indicate early signs of emphysema.
Related Concept Videos
Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Chronic Obstructive Pulmonary Disease II: Emphysema
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Radiological Investigation II: MRI and Ventilation Perfusion Scan
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...

